INmune Bio Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from INmune Bio Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Tangible Net Worth Ratio: Of every $100 of net worth, $100 is tangible; the rest is goodwill and other intangibles, often from buying other companies. More tangible than almost all Healthcare companies in United States.
- Tangible Assets Ratio: Of every $100 the company owns, $100 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles. More tangible than 98% of Healthcare companies in United States.
- Steadiness Ratio: Sales grew in 1 of the last 3 years; profit grew in 0 of 3. Less steady than 86% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
1/3 · 0/3Sales grew in 1 of the last 3 years; profit grew in 0 of 3.
Less steady than 86% of Healthcare companies in United States.
Growth Efficiency Ratio
—Sales fell 87%
Sales fell 87% in 3 years, so extra profit per extra sales cannot be measured.
Asset Productivity Ratio
-87% / -60%In 3 years sales changed by -87% while total assets changed by -60%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
-36.2×Operating cash was negative last year, while some debt falls due within a year.
Lower than 66% of Healthcare companies in United States.
Cash Cushion Ratio
+55%Cash, after subtracting all debt, equals 55% of its market value (net cash).
Higher than 78% of Healthcare companies in United States.
Tangible Assets Ratio
100%Of every $100 the company owns, $100 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 98% of Healthcare companies in United States.
Tangible Net Worth Ratio
100%Of every $100 of net worth, $100 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than almost all Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (12)
INmune Bio Inc. made a loss over the last year. INmune Bio Inc. owes $0.24 for every $1 it owns. INmune Bio Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossINmune Bio Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
2.10The share price is 2.10 times INmune Bio Inc.'s book value per share, lower than 57% of Healthcare companies in United States.
Market cap
$43 MThe total market value of all of INmune Bio Inc.'s shares at today's price (share price × number of shares), smaller than 76% of Healthcare companies in United States. PosiCap size class: Micro Cap.
Net worth (book value)
$20 MWhat INmune Bio Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$0.73Net worth divided by the number of shares. The share price of $1.54 is 2.1 times this, which is the P/B above.
Return on equity (ROE)
-74.8%INmune Bio Inc. lost 74.8% of its shareholders' money over the last year, lower than 63% of Healthcare companies in United States.
Owes vs Owns
0.24×INmune Bio Inc. owes $0.24 for every $1 it owns (low), lower than 67% of Healthcare companies in United States.
Dividend yield
NoneINmune Bio Inc. does not currently pay a dividend.
Revenue growth
+257%Revenue rose 257% in the year to Dec 2025, and shrank 49% a year on average over 3 years.
Profit growth
LossINmune Bio Inc. made a loss in each of the last two years.
Profit margin
-91866.0%INmune Bio Inc. lost $91866 for every $100 of revenue.
Cash vs debt
Net cashINmune Bio Inc. held $24 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For INmune Bio Inc.: $43 M ÷ $20 M (30 Jun 2026) = 2.1.
What is INmune Bio Inc.'s return on equity?
INmune Bio Inc. lost 74.8% of its shareholders' money over the last year, lower than 63% of Healthcare companies in United States.
How much does INmune Bio Inc. owe compared with what it owns?
INmune Bio Inc. owes $0.24 for every $1 it owns (low), lower than 67% of Healthcare companies in United States.
Does INmune Bio Inc. pay a dividend?
No. INmune Bio Inc. does not currently pay a dividend.
Is INmune Bio Inc.'s revenue growing?
Revenue rose 257% in the year to Dec 2025, and shrank 49% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.